Brief: Tarsus Announces Topline Results From Phase 2a Trial Evaluating TP-05 (lotilaner) for Prevention of Lyme Disease

Tarsus Pharmaceuticals

22/02/2024 14:51

Feb 22 (Reuters) - Tarsus Pharmaceuticals Inc  TARS.O :
    * TARSUS ANNOUNCES POSITIVE TOPLINE RESULTS FROM CARPO, A
PHASE 2A
PROOF-OF-CONCEPT “TICK-KILL” TRIAL EVALUATING TP-05 (LOTILANER)
FOR THE PREVENTION OF LYME DISEASE
    * TARSUS ANNOUNCES POSITIVE TOPLINE RESULTS FROM CARPO, A
PHASE 2A
PROOF-OF-CONCEPT “TICK-KILL” TRIAL EVALUATING TP-05 (LOTILANER)
FOR THE PREVENTION OF LYME DISEASE
    * TARSUS PHARMACEUTICALS INC - BOTH HIGH AND LOW DOSES OF
TP-05
DEMONSTRATED A STATISTICALLY SIGNIFICANT BENEFIT IN KILLING
TICKS COMPARED TO PLACEBO
    * TARSUS PHARMACEUTICALS INC - NO STATISTICALLY SIGNIFICANT
DIFFERENCES IN TICK MORTALITY WERE OBSERVED BETWEEN TWO TP-05
TREATMENT ARMS
    * TARSUS PHARMACEUTICALS INC - TP-05 WAS GENERALLY WELL
TOLERATED

Source text for Eikon:  ID:nGNXbVmdsd 
Further company coverage:  TARS.O 

 ((Reuters.Briefs@thomsonreuters.com;))